Warning letterPosted October 13, 2026
FDA warning letter to Lovelace Biomedical Research Institute
Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies
FDA posted a warning letter to Lovelace Biomedical Research Institute on October 13, 2026; the letter is dated October 6, 2026. Subject: Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies. Issuing office: Center for Drug Evaluation and Research (CDER).
On the record
- Company
- Lovelace Biomedical Research Institute
- Subject
- Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Letter dated
- 2026-10-06
- Posted by FDA
- 2026-10-13
- Source
- FDA warning letters ↗
CFR cited
The record cites 1 section of 21 CFR Part 58.
The full record
An account shows the violations FDA described and each CFR section it cited.
What a warning letter is
A warning letter is FDA's notice to a company that it found significant violations of federal requirements. FDA asks for a written response, normally within 15 working days. The letter is advisory: it states the agency's position and is not a final agency action.
More
Watch Lovelace Biomedical Research Institute
A free account shows the last 7 days of every record. Pro adds a watchlist: one email when FDA acts on a company you name.
From FDA warning letters. The record may have changed since it was read.
Approve Suite is not affiliated with FDA, or with Lovelace Biomedical Research Institute.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.